Katie Pryor

Katie is an intellectual property lawyer with particular expertise in the life sciences sector. With dual qualifications in law and science, she specialises in advising on matters relating to highly complex technical subject matter, and has a keen interest in the fields of personalised medicine and cancer therapeutics.  

Katie has advised a number of global pharmaceutical companies on European IP strategy regarding high-value products, particularly in relation to patent validity and infringement, as well as freedom to operate. She has worked on various multi-jurisdictional IP disputes, involving proceedings before the UK High Court and Court of Appeal, the European Patent Office, the Federal Court of Australia and the High Court of Australia.  

Katie also provides pro bono assistance to a variety of clients, in pursuit of causes such as raising mental health awareness and advancing racial equality.   

Katie's recent experience includes advising:

• Foundation Medicine, Inc., a subsidiary of the Roche group, on a multi-jurisdictional patent dispute concerning its next generation sequencing-based companion diagnostic for the analysis of tumor alterations, FoundationOne®Liquid CDx 
• Ariosa Diagnostics on a multi-jurisdictional patent dispute concerning its Harmony® non-invasive prenatal genetic diagnostic test, including a defence of patent infringement proceedings in the Patents Court
• Takeda on the pan-European enforcement of its patents relating to VELCADE® (bortezomib), used in the treatment of cancer
• CSL Limited, regarding a UK revocation action as part of its broader European strategy in relation to its C1-esterase inhibitor therapy, Haegarda®, including freedom to operate
• Roche on pan-European strategy regarding various patent matters

Recent blog posts
 

• How can genetic data collected by in vitro diagnostics providers be legitimately processed under the General Data Protection Regulation?
• Challenges with anonymising genetic data
• Anonymising genetic data – some particular pitfalls
• Processing genetic data on the basis of consent
• Processing genetic data on the basis of the scientific research exemption